Article in Sexual and reproductive health matters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Serah GitomeClinical Research Scientist, Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0009-0002-3371-4213
Petina MusaraSocial Scientist, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0001-9668-4344
Miria ChitukutaSocial Scientist, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0002-7345-0251
Felix MhlangaSenior Lecturer, Department of Obstetrics and Gynecology, College of Health Sciences, University of Zimbabwe; Principal Investigator, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0003-3294-3567
Bismark MatevekeObstetrician & Gynecologist, Honorary lecturer, Department of Obstetrics and Gynecology, College of Health Sciences, University of Zimbabwe.ORCID 0000-0003-1594-4859
Thandiwe ChirendaRegistered Nurse/Midwife, Clinical Research Coordinator, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.
Nyaradzo MgodiClinical Research Site Leader, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0002-3085-5259
Prisca MuteroSocial Scientist, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.
Allen MatubuLaboratory Director, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0001-5361-7686
Gift CharekaCoordinator, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0002-0529-877X
Charles ChasakaraCommunity Engagement Coordinator, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0002-3717-8617
Caroline MurombedziResearch Pharmacist, University of Zimbabwe Clinical Trials Research Center, Harare, Zimbabwe.ORCID 0000-0002-7032-2318
Tinei MakurumureLaboratory Director, Mercy-Care Fertility Centre, Harare, Zimbabwe.
Carolyn Smith-HughesAssociate Director of Evidence Translation, Department of Epidemiology and Biostatistics, San Francisco, CA, USA.ORCID 0000-0002-8216-7634
Elizabeth BukusiSenior Principal Clinical Research Scientist, Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-2031-2808
Craig R CohenProfessor, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8654-6634
Stephen ShiboskiProfessor, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9257-2609
Lynae DarbesProfessor, Department of Health Behavior and Biological Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-4738-6812
George W RutherfordProfessor, Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0707-8287
Z Michael ChirenjeProfessor, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA; Professor, Department of Obstetrics and Gynecology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID 0000-0003-3538-5150
Joelle M BrownAssociate Professor, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA; Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6044-2906
Funding
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Impact and Cost-effectiveness of Safer Conception Strategies for HIV PreventionK01MH100994 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BROWN, JOELLE MORGAN · 2013 to 2017
Decision-making on childbearing and safer conception use in HIV sero-different couples involves an intricate balance of individual desires and perceived HIV acquisition risk. This paper addresses an important knowledge gap regarding HIV sero-different couples' considerations and the relationship and power dynamics involved when deciding to use a safer conception method. Between February and June 2019, we conducted semi-structured in-depth interviews among 14 men and 17 women, representing 17 couples, who exited the SAFER study - a pilot study assessing the feasibility, acceptability and cost-effectiveness of a safer conception programme for HIV sero-different couples in Zimbabwe. All couples in SAFER were provided with a choice of safer conception methods and were followed for up to 12 months of pregnancy attempts and 3 months following pregnancy. While couples generally perceived their safer conception discussions to be easy and consensus-driven, the decision-making process also involved complex gender dynamics and trade-offs in relationship power, which resulted in differing interpretations of what constituted a joint or shared couple decision. Participants regarded effective couple communication as an essential component of and precursor to good safer conception conversations and requested additional training in couple communication. Couples relied on information from healthcare providers to kickstart their safer conception discussions. Safer conception programmes should address relationship power imbalances, promote effective couple communication and offer healthcare provider support to enable HIV sero-different couples to make informed choices about conception in a manner that upholds their safety and reproductive autonomy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.